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reamble
he American College of Cardiology Foundation (ACCF)
d the American Heart Association (AHA) support their
embers’ goal to improve the prevention and care of cardio-
scular diseases through professional education, research,
d development of guidelines and standards and by fostering
licy that supports optimal patient outcomes. The ACCF and
HA recognize the importance of the use of clinical data
andards for patient management, assessment of outcomes,
d conduct of research, and the importance of defining the
ocesses and outcomes of clinical care, whether in random-
ed trials, observational studies, registries, or quality-
provement initiatives.
Hence, clinical data standards strive to define and standard-
e data relevant to clinical topics in cardiology, with the
imary goal of assisting data collection by providing a
atform of data elements and definitions applicable to
rious conditions. Broad agreement on a common vocabu-
ry with reliable definitions used by all is vital to pool and/or
mpare data across studies to promote interoperability of
ectronic health records (EHRs) and to assess the applica-
lity of research to clinical practice. The increasing national
cus on adoption of certified EHRs along with financial
centives for providers to demonstrate “meaningful use” of
ose EHRs to improve healthcare quality render even more
perative and urgent the need for such definitions and
andards. Therefore, the ACCF and AHA have undertaken to
fine and disseminate clinical data standards—sets of stan-
rdized data elements and corresponding definitions—to
llect data relevant to cardiovascular conditions. The ulti-
ate purpose of clinical data standards is to contribute to the
frastructure necessary to accomplish the ACCF/AHA mis-
on of fostering optimal cardiovascular care and disease
evention and building healthier lives, free of cardiovascular
seases and stroke.
The specific goals of clinical data standards are
To establish a consistent, interoperable, and universal
clinical vocabulary as a foundation for both clinical care
and clinical research.
To promote the ubiquitous use of EHRs and facilitate the
exchange of data across systems through harmonized,
standardized definitions of key data elements.
To facilitate the further development of clinical registries,
quality- and performance-improvement programs, out- stcomes evaluations, and clinical research, including the
comparison of results within and across these initiatives.
The key elements and definitions are a compilation of
riables intended to facilitate the consistent, accurate, and
producible capture of clinical concepts; standardize the
rminology used to describe cardiovascular diseases and
ocedures; create a data environment conducive to the
sessment of patient management and outcomes for quality
d performance improvement and clinical and translational
search; and increase opportunities for sharing data across
sparate data sources. The ACCF/AHA Task Force on
linical Data Standards selects cardiovascular conditions and
ocedures that will benefit from creation of a data standard
t. Experts in the subject are selected to examine/consider
isting standards and develop a comprehensive, yet not
haustive, data standard set. When undertaking a data
llection effort, only a subset of the elements contained in a
inical data standards listing may be needed, or conversely,
ers may want to consider whether it may be necessary to
llect some elements not listed. For example, in the setting
a randomized clinical trial of a new drug, additional
formation would likely be required regarding study proce-
res and drug therapies.
The ACCF and AHA recognize that there are other
tional efforts to establish clinical data standards, and every
tempt is made to harmonize newly published standards with
isting standards. Writing committees are instructed to
nsider adopting or adapting existing nationally recognized
ta standards if the definitions and characteristics are useful
d applicable to the set under development. In addition, the
CCF and AHA are committed to continually expanding
eir portfolio of data standards and will create new standards
d update existing standards as needed to maintain their
rrency and promote harmonization with other standards as
alth information technology and clinical practice evolve.
The Health Insurance Portability and Accountability Act
ivacy regulations, which went into effect in April 2003,
ve heightened all practitioners’ awareness of our profes-
onal commitment to safeguard our patients’ privacy. The
ealth Insurance Portability and Accountability Act privacy
gulations (1) specify which information elements are con-
dered “protected health information.” These elements may
t be disclosed to third parties (including registries and
search studies) without the patient’s written permission.
rotected health information may be included in databases
ed for healthcare operations under a data use agreement.
esearch studies using protected health information must be
viewed by an institutional review board or a privacy board.
We have included identifying information in all clinical
ta standards to facilitate uniform collection of these
ements when appropriate. For example, a longitudinal
inic database may contain these elements because access
restricted to the patient’s caregivers. Conversely, regis-
ies may not contain protected health information unless
ecific permission is granted by each patient. These fields
e indicated as protected health information in the data
andards.
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akes every effort to avoid any actual or potential conflicts of
terest that may arise as a result of an outside relationship or
personal, professional, or business interest of a member of
e writing panel. Specifically, all members of the writing
mmittee were required to submit a disclosure form showing
l such relationships that might be perceived as real or
tential conflicts of interest. These statements were re-
ewed by the ACCF/AHA Task Force on Clinical Data
tandards, reported orally to all members of the writing panel
the first meeting, and updated as changes occur. Writing
mmittee members’ relationships with industry are listed in
ppendix 1. Official reviewers’ relationships with industry
e listed in Appendix 2.
In clinical care, caregivers communicate with each other
rough a common vocabulary. In an analogous fashion, the
tegrity of clinical research depends on firm adherence to
especified procedures for patient enrollment and follow-up;
ese procedures are guaranteed through careful attention to
finitions enumerated in the study design and case report
rms. When data elements and definitions are standardized
ross studies, comparison, pooled analysis, and meta-
alysis are enabled, thus deepening our understanding of
dividual studies.
The recent development of quality-performance measure-
ent initiatives, particularly those for which the comparison
providers is an implicit or explicit aim, has further raised
areness about the importance of data standards. Indeed, a
ide audience, including nonmedical professionals such as
yers, regulators, and consumers, may draw conclusions
out care and outcomes. To understand and compare care
tterns and outcomes, the data elements that characterize
em must be clearly defined, consistently used, and properly
terpreted, now more than ever before.
Robert C. Hendel, MD, FACC, FAHA
hair, ACCF/AHA Task Force on Clinical Data Standards
. Introduction
he vision of a seamless care environment, namely the ability
deliver continuity of care in all patient contexts across the
ectrum of caregivers and their respective environments
rough the efficient use of health information technology and
teroperable data (2), is slowly becoming a reality. To
complish this vision, the coordination of multiple complex
orkflows, processes, and technologies is required. First is
e universal use of patient-centric EHR solutions that
ntain all health-related information, including a subset
that information managed as discrete data (3). In close
ordination, the ability to use the discrete data for
ultiple purposes to meet the needs of all stakeholders is
so required. Key to accomplishing this is an authoritative
aster set of data elements that are globally accessible and
oadly implemented.
On July 28, 2010, the Centers for Medicare and Medicaid
ervices published in the Federal Register a Notice of the Final
ule titled “Medicare and Medicaid Programs: Electronic
ealth Record Incentive Program” (4). On the same day, the unffice of the National Coordinator for Health Information
echnology published a companion Final Rule, “Health Infor-
ation Technology: Initial Set of Standards, Implementation
pecifications, and Certification Criteria for Electronic Health
ecord Technology” (5). These 2 publications establish the
quirements that hospitals and eligible professionals must meet
achieve “meaningful use” of EHR solutions and thus qualify
r financial incentives as stipulated in the health information
chnology provisions of the American Recovery and Reinvest-
ent Act of 2009 (6).
The tenets of meaningful use include the implementation
d utilization of certified EHR solutions in a manner that
omotes interoperable health information, improves the
ality of health care and care coordination, and reports on
ality measures. The functionality measures that define
eaningful use (24 for hospitals and 25 for eligible
ofessionals) (4,5) are built on the premise of interoper-
le, clinically meaningful, and relevant discrete data.
nticipating the need for clinical data interchange, use of
standardized cardiovascular vocabulary was explicitly
cluded in 2009 as a proposed roadmap requirement for
rdiovascular specialty EHR certification by the Certifi-
tion Commission for Health Information Technology
CHIT), with the actual data elements required for
rtification published as a specification in the “CCHIT
ertified 2011 Cardiovascular Criteria” document (7).
Compared with more mature or naturally discrete types of
ta concepts such as laboratory results (8), interoperability
data representing information acquired historically or
ring a patient encounter (e.g., history, symptoms and signs
heart failure) remains rudimentary. Interoperability is
fined at 2 levels: functional or syntactical interoperability,
e ability of 2 systems to exchange information (involving
rdware, software, operating systems, communications pro-
cols, and all components that serve to move data from one
stem to another); and semantic interoperability, the ability
use the information that has been exchanged (9). The
ilding block of semantic interoperability is the common
ta element (10). Fully formed data elements include meta-
ta that define, delimit, and represent the concept of the data
ement, including associated permissible values. Standard
finitions of distinct clinical concepts ensure semantic in-
roperability. In turn, semantic interoperability permits the
amless interaction of clinical (and administrative) processes
ross the continuum of care, including the ability to merge,
mpare, and leverage observations acquired across clinical
counters. Interoperable information at the data element
vel may be anticipated to stimulate the adoption and
hance performance of EHR solutions; the 2004 report of
e President’s Information Technology Advisory Committee
ecifically cited the lack of standards at the data element
vel as a primary reason for the slow rate of adoption of
HRs (11).
The facilitation of learning an accountable healthcare
stem, with the translation of knowledge acquired during
search into clinical practice, is likewise a national priority
2). One of the greatest inefficiencies of current approaches
clinical and translational research is the absence of aifying infrastructure with streamlined, 1-time data collec-
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July 5, 2011:202–22 Data Elements and Definitions for EHRon; common data terms; and cooperative use of data shared
ong researchers (13). Instead, clinical and research pro-
sses typically occur as independent parallel endeavors. For
ample, clinical evaluation findings and management deci-
ons, with accompanying test results, can be documented in
clinic note; dictated into a letter and communicated to
hers; coded for reimbursement; keyed into multiple Web-
sed systems for quality reporting, Joint Commission activ-
ies, and clinical trials; and sometime later be extracted from
tient records to support additional clinical or research
eds. If uniform data standards and terms supported by all
ese disparate systems were in place, the data could be
ptured once in the clinical workflow and then be made
ailable to all stakeholders.
Of note, this document is a slight departure from previous
ork of the ACCF/AHA Task Force on Clinical Data Standards
4) in that quite intentionally none of the clinical definitions are
iginal to this effort. Instead, this document is an aggregation of
rms and a recapitulation of definitions from libraries of
blished data terms and other data sources. In addition to
tural language definitions, the description of data elements in
is standard couples the text definitions with complete machine-
terpretable definitions, extending the investment in the creation
authoritative clinical definitions by rendering those definitions
rectly computer usable by EHR and other information tech-
logy solutions.
. Methodology
.1. Writing Committee Composition
he ACCF/AHA Task Force on Clinical Data Standards
lected members for the writing committee. The writing
mmittee consisted of 13 people with expertise in cardio-
scular medicine, EHR technologies, and medical informat-
s, and included representation from adult and pediatric
rdiovascular medicine and surgery.
.2. Relationships With Industry and
ther Entities
he ACCF/AHA Task Force on Clinical Data Standards
akes every effort to avoid any actual or potential conflicts of
terest that may arise as a result of an outside relationship or
personal, professional, or business interest of a member of
e writing panel. Specifically, all members of the writing
mmittee were required to complete and submit a disclosure
rm showing all such relationships that might be perceived
real or potential conflicts of interest. These statements are
viewed by the ACCF/AHA Task Force on Clinical Data
tandards and updated when changes occur. Authors’ and
er Reviewers’ relationships with industry and other entities
rtinent to this data standards document are disclosed in
ppendixes 1 and 2, respectively. In addition, to ensure
mplete transparency, writing committee members’ compre-
nsive disclosure information—including relationships not
rtinent to this document—is available online as a supple-
ent to this document..3. Data Element Identification, Definitions
nd Attributes, and Consensus Development
CCF/AHA data standards are team developed and vetted.
xperts in cardiovascular medicine, EHR technologies, and
edical informatics participated in the authoring of this set of
ta elements. Initiated as a reference project, a preliminary
t of candidate terms was identified by the American College
Cardiology (ACC) Informatics Committee through face-
-face and conference call meetings, polls, and e-mail
rrespondence. From the outset, it was envisioned that the
st would be the base cardiovascular terms that are univer-
lly applicable from primary care through subspecialty
rdiovascular care, inclusive of the outpatient and inpatient
vironments, to facilitate the exchange of clinical informa-
on across the continuum of care. The ACC Informatics
ommittee requested that the ACCF/AHA Task Force on
linical Data Standards formalize the effort according to the
blished process methodology (14). The task force estab-
shed the writing committee for refinement and final vetting
the list of candidate terms and management of the
formatics work product to complete the attributes sets
sociated with the terms. This was accomplished through a
ries of additional meetings, polls, and correspondence over
months in 2010, resulting in the vocabulary described in
ection 3.
The intent of this initiative was to identify a base set of
rms with maximal value according to at least one of the
iteria described below. Specifically, the target was to
entify terms that are to be available in every general
rpose EHR, that are interoperable and reusable with every
rdiovascular subspecialty EHR, and that are extendable and
usable in the clinical research and institutional, local, state,
gional, and national registry and data interchange environ-
ents. Terms relevant to adult cardiovascular disorders with
high prevalence and high burden (morbidity and mortality)
ere selected preferentially, notably coronary artery dis-
se, valvular heart disease, heart failure, atrial fibrillation/
rial flutter, and serious arrhythmias. Stated in more
lloquial terms, the focus of this effort was to identify the
ow-hanging fruit.” As such, out of the thousands of
tential cardiovascular terms, 100 data elements are
cluded in this document.
For a data element to be included in the cardiovascular
cabulary for EHRs, it had to meet 1 of the following
iteria:
Represents a waypoint in clinical care, typically as a sum-
mary representation or critical element of a more extensive
concept (e.g., procedure type and date, key procedure finding
or result).
Facilitates the assessment of delivery of quality care (e.g.,
data elements required for meaningful use quality reporting or
appropriate use criteria assessment).
Has proven value in outcomes modeling or prediction (e.g.,
Thrombolysis In Myocardial Infarction [TIMI] risk score in
acute coronary syndromes, Society of Thoracic Surgeons
(STS) morbidity and mortality risk prediction for cardiotho-
racic surgery).
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Data Elements and Definitions for EHR July 5, 2011:202–22Identifies implanted devices, particularly those that might be
subject to recall by the U.S. Food and Drug Administration
(e.g., pacemaker generator unit and pacemaker leads, pros-
thetic replacement valves).
Clinical definitions of the selected data elements are
peated verbatim where possible as previously reported in
CCF/AHA data standards documents and/or as fields within
isting registries, particularly the ACC National Cardiovas-
lar Data Registry (NCDR), the ACC PINNACLE Registry,
e AHA Get With The Guidelines Registry, and the STS
ational Database (15–22). Source documents (noted in the
ource column of each data standard table) included the
CC/AHA/HRS 2006 Key Data Elements and Definitions
r Electrophysiological Studies and Procedures” (16), the
merican College of Cardiology Key Data Elements and
efinitions for Measuring the Clinical Management and
utcomes of Patients with Acute Coronary Syndromes”
7), the “ACC/AHA/ACR/ASE/ASNC/HRS/NASCI/RSNA/
AIP/SCAI/SCCT/SCMR/SIR 2008 Key Data Elements and
efinitions for Cardiac Imaging” (18), the “ACC/AHA Key
ata Elements and Definitions for Measuring the Clinical
anagement and Outcomes of Patients with Atrial Fibrilla-
on” (19), and the “ACC/AHA Key Data Elements and
efinitions for Measuring the Clinical Management and
utcomes of Patients with Chronic Heart Failure” (20).
llowed values for each data element, such as grades of
itral regurgitation or abbreviations of the names of imaging
udies, were culled from the same literature sources and are
ted in the Value Domain column of each table.
A key focus is to perform the informatics work to build the
rtfolio of attributes for each of the data elements according to
e International Organization for Standardization/International
lectrotechnical Commission (ISO/IEC) 11179 standard
3,24), principally to facilitate adoption of these elements by
e EHR vendor community. The ISO 11179 metadata reposi-
ry standard provides a standard grammar and syntax for
scribing data elements and associated metadata that results in
ambiguous representation and interpretation of data. For
ample, Appendix 3 illustrates the description of the data
ement New York Heart Association (NYHA) class. The
riting committee, in collaboration with informaticists at the
CC and Duke Clinical Research Institute, Durham, NC, will
thor the attributes for each of the data elements. This attribute
t includes (as appropriate to the individual element) the
eferred (longhand) name of the data element, a persistent (and
iversal) set of metadata tags, the unique identifiers, definition,
nstituent source of vocabulary, permissible values, data type,
its, classification, links or relationships, purpose, and citation
d an indication of how the data element is measured. Addi-
nally, administrative attributes, such as steward, authority,
atus, and version date, are included. For the metadata tags and
entifiers, we recommend the use of the construct of the
ational Institutes of Health/National Cancer Institute Data
tandards Registry and Repository (25), informed by the exist-
g data dictionaries of the Duke Information System for
ardiovascular Care, ACC NCDR, ACC PINNACLE Registry,
d AHA Get With The Guidelines Registry. Also note that in cois publication, the data element “definition” frequently cross-
ferences other (external) resource materials rather than at-
mpting to provide a complete, self-standing definition; the
mplete definition can be found in the National Cancer Institute
ata Standards Registry and Repository.
.4. Relation to Other Standards
s described previously, the writing committee reviewed avail-
le published data standards, including those developed for
art failure, atrial fibrillation, electrophysiology, acute coronary
ndromes, and imaging, along with data definitions used in
veral national registries (15–22). The writing committee felt
at it was the responsibility of this multidisciplinary group to
entify (but not author) a single best definition for the selected
ta elements to facilitate the uniform adoption of these terms by
e clinical, clinical and translational research, regulatory, qual-
and outcomes, and EHR communities. Some adjustments to
isting published definitions were made to eliminate verbiage
t relevant to the definition itself (e.g., instructions such as the
rase “indicate whether the patient has ...” have been elimi-
ted). In these cases, the writing committee retained only the
finition proper.
The writing committee believes that the ACCF/AHA should
the steward, that is, the organizations taking responsibility for
data element, for terms that are explicitly cardiovascular (e.g.,
gina class, mitral valve stenosis). Terms specific to other
sciplines (e.g., chronic kidney disease) should be the respon-
bility of the respective society; generic terms (e.g., systolic
ood pressure) that are implicit and sufficiently commoditized
uld be the responsibility of either the ACCF/AHA or other
ciety or organization that assumes stewardship. However, to
vance this initiative, the ACCF/AHA Task Force on Clinical
ata Standards has assumed the responsibility for the terms
ithout another identified steward in the National Cancer Insti-
te Data Standards Registry and Repository, pending assump-
n of that responsibility by another society or organization.
.5. Peer Review, Public Review,
nd Board Approval
he cardiovascular data elements and definitions were inde-
ndently reviewed by official appointees of the ACC, AHA,
d ACCF/AHA Task Force on Clinical Data Standards. To
crease its applicability, this document was posted on the
CC Web site for a 30-day public comment period from
ovember 5, 2010, through December 5, 2010. The docu-
ent was then approved by the ACCF Board of Trustees on
arch 11, 2011, and by the AHA Science Advisory and
oordinating Committee on March 14, 2011. The writing
mmittee anticipates that these data standards will require
view and updating, just as with other published guidelines,
rformance measures, and appropriateness criteria. The
riting committee will review the set of data elements on a
riodic basis, starting with the anniversary of publication of
e standards, to ascertain whether modifications should be
nsidered.
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July 5, 2011:202–22 Data Elements and Definitions for EHR.6. Intended Use
he writing committee anticipates that the cardiovascular
cabulary for EHRs will be the universal and base set of
rdiovascular terms to be implemented in all EHR solutions.
here is not an attempt to provide a comprehensive or
mplete list of terms; instead, the goal is to identify terms
at have maximal clinical and research utility across the
idest spectrum of clinical settings. An emphasis on harmo-
zation should be evident, typically favoring the most recent
nsensus publication. As such, these data standards will
ove useful in several settings:
Clinical care, particularly transitions of care between
and among providers and between outpatient and hos-
pital settings. Data standards will improve communica-
tion and care coordination, reduce redundant data col-
lection, and enable clinical decision support and disease
management tools.
Clinical workflow, specifically facilitating a “floor” stan-
dard regarding the collection of discrete data elements in
the context of caring for the patient with cardiovascular
disease. Discreet data collection is critical to the success
of implementation of any EHR and is required to meet
the goals of data collection and exchange. In this
regard, the number of defined data elements has been
limited to minimize the documentation burden on the
clinical community.
Clinical query, such as device recalls or changes in
therapy predicated by the findings of well-controlled trials
or provider notification by regulatory authorities.
Quality assessment/performance measurement, inclusive of
the data elements for quality reporting for meaningful use,
along with reporting to other parties such as care organiza-
tions, payers, regulators, consumers, and national registries,
such as the ACC NCDR and AHA’s Get With The Guide-
lines Registry.
Clinical research, including registries, prospective observa-
tional and longitudinal studies, and randomized controlled
trials. Meta-analyses will be particularly strengthened by
consistently implemented data elements across EHR systems.
A modular approach to the use of these terms is implicit.
he intent is not to require the EHR vendor community to
eate a “cardiovascular module” that incorporates these HER
ta elements but instead to have the terms tightly integrated
ithin the body of the EHR solution, with the terms used
here appropriate on an as-needed basis. Certain data
finitions are applicable only to specific situations, such
the coded mitral regurgitation grading result of a
ntriculogram, echocardiogram, or magnetic resonance
udy; outside of this context, inclusion of this field in an
HR would be nonsensical.
Furthermore, although pediatric cardiology representation
as involved in the creation of these data standards, these
andards are not intended to be the primary source of data
andards for pediatric cardiology EHRs. Data standards
ecific to pediatric and congenital cardiology are in devel-
ment. The data standards in this document, however, can
and alongside pediatric standards, with the intent of even-
al interoperability. el. Cardiovascular Data Elements
nd Definitions for Electronic
ealth Records
.1. Demographic, Administrative,
nd Diagnostic Data
he writing committee explicitly elected not to include patient
entification, demographic, and administrative information such
patient sex or site of service, diagnosis, and other fundamental
ncept terms, including data by specific medication, as defined
ta elements. Comprehensive EHR solutions are anticipated to
llect this information as discrete data. Furthermore, a robust
lution for patient identification (e.g., the unique patient iden-
er)is a universal requirement, whether within the context of
e EHR of an individual practice or the registry aggregation of
formation across multiple disparate inpatient and ambulatory
counters. Although patient age, sex, race, and ethnicity are key
ements in various risk prediction models, these data elements
e expected to be generically available in all EHR solutions and
erefore have not been listed. Similarly, because much of
eaningful use is constructed around the problem list, diagnosis
not included as a defined data element, as the presence of a
dified problem list is assumed.
.2. History and Physical Examination
rom the myriad of candidate terms, the data elements chosen
r inclusion in Table 1 are those with predictive value in risk
odels of acute and chronic cardiovascular disease, particu-
rly acute coronary syndromes, ST-segment elevation acute
yocardial infarction, heart failure, and sudden death. Infor-
ation about the medical history and risk factors is key in
propriate use assessment, quality-performance measure-
ent, clinical research, and clinical care. The elements
osen are purposely intended to replicate commonly col-
cted data elements and reflect current consensus guidelines
the classification of disease states. The value domain of
ese data elements purposely includes as optional the
oices of “null” (and where appropriate, “no”) to reflect the
pical workflow of documenting only pertinent positives
.e., charting by exception). Data elements in the vocabulary
clude physician-classified symptom scales (e.g., NYHA
assification of functional class and Canadian Cardiovascu-
r Society classification of anginal severity). These may be
pplemented by patient-reported outcome tools (e.g., Kansas
ity Cardiomyopathy Questionnaire for heart failure and
eattle Angina Questionnaire for angina). The writing com-
ittee acknowledges that all potential elements are not
cluded and that additional detail may be needed, depending
the use case.
.3. Laboratory Results
nly 11 laboratory testing elements are listed in Table 2,
flecting the laboratory tests most likely to be followed
ngitudinally by cardiologists for the purpose of cardiovas-
lar risk mitigation via direct interventional management of
e laboratory abnormalities. These laboratory result data
ements are useful for assessing the appropriate use of
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Data Elements and Definitions for EHR July 5, 2011:202–22ble 1. History and Physical Examination Elements
Data Field Definition Value Domain Notes Source
rrent Status
est pain (angina) or
ginal equivalent
Chest pain, other discomfort, dyspnea, or other sign or symptom possibly,
probably, or definitely consistent with myocardial ischemia or infarction:
● Noncardiac: signs/symptoms inconsistent with myocardial ischemia
● Atypical: signs/symptoms possibly consistent with myocardial ischemia but not
typical of classical angina pectoris (or anginal equivalent)
● Stable angina: angina pectoris (or anginal equivalent) without a recent change
in frequency or pattern. Angina is relieved by rest and/or
sublingual/transdermal medications.
● Variant (synonym: Prinzmetal angina, coronary vasospasm): angina pectoris (or
anginal equivalent) that usually occurs spontaneously and, unlike typical
angina, nearly always occurs at rest and does not require physical exertion. It
is frequently associated with transient ST-segment elevation.
● Unstable angina/NSTEMI: angina pectoris (or anginal equivalent) with any of the
following features:
– Symptoms at rest and prolonged, usually 20 min
– New-onset symptoms of CCS grade III or grade IV severity
– Recent acceleration of symptoms with an increase in severity of at least
1 CCS grade to CCS grade III or grade IV severity
– Symptoms associated with positive biomarkers for myocardial necrosis but
without ST elevation on ECG
● Acute STEMI
Noncardiac
Atypical
Stable angina
Variant
Unstable angina/NSTEMI
Acute STEMI
[null]
ACCF/AHA Cardiac Imaging
Data Standard (18)
gina grade [CCS] To grade symptoms or signs in patients with suspected or presumed stable angina
(or anginal equivalent) according to the CCS grading scale:
● Class I: ordinary physical activity, such as walking or climbing stairs, does not
cause angina. Angina occurs with strenuous, rapid, or prolonged exertion at
work or recreation.
● Class II: slight limitation of ordinary activity. Angina occurs on walking or
climbing stairs rapidly, walking uphill, walking or climbing stairs after meals,
or in cold, in wind, or under emotional stress, or only during the few hours
after awakening. Angina occurs on walking 2 blocks on the level and
climbing 1 flight of ordinary stairs at a normal pace and in normal
conditions.
● Class III: marked limitation of ordinary physical activity. Angina occurs on
walking 1 to 2 blocks on the level and climbing 1 flight of stairs in normal
conditions and at a normal pace.
● Class IV: inability to perform any physical activity without discomfort–anginal
symptoms may be present at rest.
1
2
3
4
[null]
ACCF/AHA Acute Coronary
Syndrome Data Standards
(17), Campeau L. Letter:
grading of angina pectoris.
Circulation. 1976;54:522–3 (26).
art failure class
YHA]
To classify symptoms or signs in patients with suspected or presumed heart failure
according to the NYHA classification scale:
● Class I: without limitations of physical activity. Ordinary physical activity does
not cause undue fatigue, palpitations, or dyspnea.
● Class II: slight limitation of physical activity. The patient is comfortable at rest.
Ordinary physical activity results in fatigue, palpitations, or dyspnea.
● Class III: marked limitation of physical activity. The patient is comfortable at
rest. Less than ordinary activity causes fatigue, palpitations, or dyspnea.
● Class IV: inability to carry on any physical activity without discomfort. Heart
failure symptoms are present even at rest or with minimal exertion.
1
2
3
4
[null]
The Criteria Committee of the
New York Heart Association.
In Nomenclature and Criteria
for Diagnosis of Diseases of
the Heart and Great Vessels.
9th ed. Boston, MA: Little,
Brown & Co; 1994:253–6 (27).
ncope Sudden loss of consciousness with loss of postural tone, not related to anesthesia,
with spontaneous recovery as reported by patient or observer. Patients may
experience syncope when supine.
Yes
[No]
[null]
ACCF/AHA Electrophysiology
Data Standards (16)
te of syncope Indicate date of the most recent event if there is a history of 1 event. Date
[null]
Minimum data: year ACCF/AHA Electrophysiology
Data Standards (16)
st History
istory of ...”)
pertension* Current or previous diagnosis of hypertension, defined as any of the following:
● History of hypertension diagnosed and treated with medication, diet,
and/or exercise
● On at least 2 separate occasions, documented blood pressure 140 mm Hg
systolic and/or 90 mm Hg diastolic in patients without diabetes or chronic
kidney disease, or blood pressure 130 mm Hg systolic or 80 mm Hg
diastolic in patients with diabetes or chronic kidney disease
● Currently on pharmacological therapy for treatment of hypertension
Yes
[No]
[null]
ACCF/AHA Cardiac Imaging
Data Standards (18)
slipidemia Current or previous diagnosis of dyslipidemia according to National Cholesterol
Education Program criteria, defined as any 1 of the following:
● Total cholesterol 200 mg/dL (5.18 mmol/L)
● LDL 130 mg/dL (3.37 mmol/L)
● HDL 40 mg/dL (1.04 mmol/L) in men and 50 mg/dL (1.30 mmol/L)
in women
Yes
[No]
[null]
ACCF/AHA Cardiac Imaging
Data Standards (18)
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Data Field Definition Value Domain Notes Source
betes History of diabetes diagnosed and/or treated by a physician. American Diabetes
Association criteria include documentation of the following:
● Hemoglobin A1c 6.5%; or
● Fasting plasma glucose 126 mg/dL (7.0 mmol/L); or
● 2-Hour plasma glucose 200 mg/dL (11.1 mmol/L) during oral glucose
tolerance test; or
● In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis,
a random plasma glucose level 200 mg/dL (11.1 mmol/L)
This does not include gestational diabetes.
Yes–type 1
Yes–type
2
[No]
[null]
ADA Position Statement:
Standards of Medical Care in
Diabetes–2011 (28)
bacco use* Current or previous use of any tobacco product, including cigarettes, cigars, pipes,
and chewing tobacco, captured as smoking status:
● Current everyday smoker
● Current some day smoker
● Former smoker
● Never smoker
● Smoker, current status unknown
Current everyday smoker
Current some day smoker
Former smoker
Never smoker
Smoker, current status
Unknown
[null]
CMS Meaningful Use (29)
ronic lung disease Documented history of chronic lung disease (e.g., chronic obstructive pulmonary
disease, chronic bronchitis) or currently receiving long-term treatment with inhaled
or oral pharmacological therapy (e.g., beta-adrenergic agonist, anti-inflammatory
agent, leukotriene receptor antagonist, or steroid) for the indication of lung disease.
Date of onset (first diagnosis) may be helpful.
Yes
No
[null]
ACCF/AHA Atrial Fibrillation
Data Standards (19)
ronic kidney disease Current or previous history of chronic kidney disease, captured as current status.
Chronic kidney disease is defined as either kidney damage or GFR
60 mL/min/1.73 m2 for 3 months. Kidney damage is defined as pathologic
abnormalities or markers of damage, including abnormalities in blood or urine tests
or imaging studies:
● Stage 0—No known kidney disease
● Stage 1—Kidney damage with normal or high—GFR 90 mL/min/1.73 m2
● Stage 2—Kidney damage with mildly decreased—GFR 60–89 mL/min/1.73 m2
● Stage 3—Moderately decreased—GFR 30–59 mL/min/1.73 m2
● Stage 4—Severely decreased—GFR 15–29 mL/min/1.73 m2
● Stage 5—Kidney failure—GFR 15 mL/min/1.73 m2 or on dialysis
0
1
2
3
4
5
[null]
ACCF/AHA, NKF KDOQI
Advisory Board. KDOQI
clinical practice guidelines for
chronic kidney disease:
evaluation, classification, and
stratification. Am J Kidney Dis.
2002;39Suppl 2:S65 (30).
lysis Requirement for dialysis treatment, including hemodialysis and peritoneal dialysis Yes
[No]
[null]
cit drug use Documented history of current, recent, or remote abuse of any illicit drug (e.g.,
cocaine, methamphetamine, marijuana) or controlled substance
Yes
[No]
[null]
ACCF/AHA Atrial Fibrillation
Data Standards (19)
infection HIV infection diagnosed by a physician or qualified medical-care provider
documented in a medical record and based on the following laboratory criteria:
● Positive result from an HIV antibody screening test (e.g., reactive EIA*)
confirmed by a positive result from a supplemental HIV antibody test (e.g.,
Western blot or indirect immunofluorescence assay test); or
● Positive result or report of a detectable quantity (i.e., within the established
limits of the laboratory test) from any of the following HIV virologic (i.e., non-
antibody) tests:
– HIV nucleic acid (DNA or RNA) detection test (e.g., PCR)
– HIV p24 antigen test, including neutralization assay
– HIV isolation (viral culture)
Oral reports of prior laboratory test results are not acceptable.
Yes
[No]
[null]
CDC–Revised Surveillance
Case Definitions for HIV
Infection Among Adults,
Adolescents, and Children
Aged 18 Months and for
HIV Infection and AIDS Among
Children Aged 18 Months to
13 Years—United States,
2008 (31)
ial arrhythmias Current or previous history of any of the following atrial arrhythmias, captured as
type of arrhythmia:
● First detected AF
● Paroxysmal AF: AF is self-terminating within 7 days of recognized onset
● Persistent AF: AF is not self-terminating within 7 days or is terminated
electrically or pharmacologically
● Permanent AF: cardioversion failed or not attempted
● Atrial flutter
● Atrial tachycardia
● Sick sinus syndrome
AF, first detected
AF, paroxysmal
AF, persistent
AF, permanent
Atrial flutter
Atrial tachycardia
Sick sinus syndrome
[No]
[null]
Can select any of
the above choices;
“No” is exclusive
ACCF/AHA Electrophysiology
Data Standards (16)
roxysmal
praventricular
hycardia
Current or previous history of paroxysmal supraventricular tachycardia Yes
[No]
[null]
ACCF/AHA Electrophysiology
Data Standards (16)
ntricular arrhythmias VT, sustained
VT, nonsustained
VF
[No]
[null]
Current or previous history of
any of the following ventricular
arrhythmias, captured as type
of arrhythmia:
● VT, sustained
● VT, nonsustained
● VF
Can select any of
the VT/VF choices;
“No” is exclusive
ACCF/AHA Chronic Heart
Failure Data Standards (20)
nous
omboembolism
Current or previous history of DVT or pulmonary embolism Yes—DVT
Yes—Pulmonary embolism
[No]
[null]
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Data Field Definition Value Domain Notes Source
pression Current or previous diagnosis of depression or documentation of a depressed mood
or affect
Yes
[No]
[null]
ACCF/AHA Chronic Heart
Failure Data Standards (20)
ronary artery
ease*
Current or previous history of any of the following:
● Coronary artery stenosis 50% (by cardiac catheterization or other modality of
direct imaging of the coronary arteries)
● Previous CABG surgery
● Previous PCI
● Previous MI
Yes
[No]
[null]
ACCF/AHA Cardiac Imaging
Data Standards (18)
rebral artery disease Current or previous history of any of the following:
● Ischemic stroke: infarction of central nervous system tissue whether
symptomatic or silent (asymptomatic)
● TIA: transient episode of neurological dysfunction caused by focal brain, spinal
cord, or retinal ischemia without acute infarction
● Noninvasive or invasive arterial imaging test demonstrating 50% stenosis of
any of the major extracranial or intracranial vessels to the brain
● Previous cervical or cerebral artery revascularization surgery or percutaneous
intervention.
This does not include chronic (nonvascular) neurological diseases or other acute
neurological insults such as metabolic and anoxic ischemic encephalopathy.
Yes
[No]
[null]
ACCF/AHA Cardiac Imaging
Data Standards (18);
Nomenclature for Vascular
Diseases (32); 2009 AHA/ASA
Definition and Evaluation of
Transient Ischemic Attack (33)
ripheral artery
ease
Current or previous history of peripheral artery disease (lower extremity from iliac
to tibials and upper extremity from subclavian to brachials. Excludes renal,
coronary, cerebral, and mesenteric vessels and aneurysms). Major symptoms can
include
● Claudication relieved by rest
● Amputation for severe arterial vascular insufficiency
● Vascular reconstruction, bypass surgery, or percutaneous revascularization in
the arteries of the lower or upper extremities
● Positive noninvasive test (e.g., ankle brachial index 0.90, ultrasound, MR or
CT imaging of 50% diameter stenosis in any peripheral artery (i.e.,
subclavian, femoral, iliac) or angiographic imaging
Yes
[No]
[null]
Nomenclature for Vascular
Diseases (32)
rta disease Current or previous history of disease of the thoracic, thoracoabdominal, or
abdominal aorta (typically aneurysm)
Yes
[No]
[null]
Nomenclature for Vascular
Diseases (32)
nal artery disease Current or previous history of disease of the main renal arteries or extrarenal
branches
Yes
[No]
[null]
Nomenclature for Vascular
Diseases (32)
ocardial infarction The term myocardial infarction should be used when there is evidence of
myocardial necrosis in a clinical setting consistent with myocardial ischemia. Under
these conditions, any 1 of the following criteria meets the diagnosis for MI:
● Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at
least 1 value above the 99th percentile of the URL together with evidence of
myocardial ischemia with at least 1 of the following:
– Symptoms of ischemia
– ECG changes indicative of new ischemia [new ST-T changes or new LBBB]
– Development of pathological Q waves in the ECG
– Imaging evidence of new loss of viable myocardium or new regional wall
motion abnormality
Yes
[No]
[null]
Universal Definition of MI (34)
● Sudden unexpected cardiac death, involving cardiac arrest, often with
symptoms suggestive of myocardial ischemia, and accompanied by
presumably new ST-segment elevation or new LBBB, and/or evidence of fresh
thrombus by coronary angiography a time before the appearance of cardiac
biomarkers in the blood.
● For PCI in patients with normal baseline indicative of periprocedural myocardial
necrosis. By convention, increases of biomarkers 399th percentile URL
have been designated as PCI-related MI. A subtype related to a documented
stent thrombosis is recognized.
● For CABG in patients with normal baseline troponin values, elevations of
cardiac biomarkers above the 99th percentile URL are indicative of
periprocedural myocardial necrosis. By convention, increases of biomarkers
599th percentile URL plus either new pathological Q waves or new or
imaging evidence of new loss of viable myocardium have been designated as
defining CABG-related MI.
● Pathological findings of an acute MI
te of myocardial
arction
Date of documented MI. Indicate the date of most recent MI if there is a history of
more than one.
Date
[null]
Minimum data is
year
ACCF/AHA Cardiac Imaging
Data Standards (18)
dden cardiac arrest [Sudden] cardiac arrest is the sudden cessation of cardiac activity. The victim
becomes unresponsive with no normal breathing and no signs of circulation. If
corrective measures are not taken rapidly, this condition progresses to sudden
death. Cardiac arrest should be used to signify an event as described above that is
reversed, usually by CPR and/or defibrillation or cardioversion or cardiac pacing.
Sudden cardiac death should not be used to describe events that are not fatal.
Yes
No
[null]
ACCF/AHA Electrophysiology
Data Standards (16)
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July 5, 2011:202–22 Data Elements and Definitions for EHRrdiovascular procedures, for quality-performance measure-
ent, and for meaningful use reporting. As with elements of
e history and physical, the writing committee acknowledges
at the list is a limited subset of the universe of laboratory
lues with potential cardiovascular relevance. Laboratory
easurements can be in Système International d’Unites (SI
its; e.g., mmol/L) or conventional units (e.g., mg/dL).
.4. Diagnostic and Therapeutic Procedures
iagnostic and therapeutic cardiovascular procedures are
ntral to the evaluation and management of patients with
rdiovascular disease. Consistent with the other sections,
osen data elements include those with specific value in
presenting a waypoint of care (e.g., procedure and date), in
sessing process in delivery of quality care (e.g., appropriate
e criteria assessment), that are predictive of outcome (e.g.,
y findings), or that identify implanted devices. The list is
ble 1. Continued
Data Field Definition
te of cardiac arrest Date of documented resuscitated cardiac arrest
art failure* Indicate if there is physician documentation or a report that the patient
a state of heart failure.
Heart failure is defined as physician documentation or a report of any o
following clinical symptoms of heart failure described as unusual dyspn
exertion, recurrent dyspnea occurring in the supine position, fluid reten
description of rales, jugular venous distention, pulmonary edema on ph
examination, or pulmonary edema on chest x-ray presumed to be card
dysfunction.
A low ejection fraction alone, without clinical evidence of heart failure,
qualify as heart failure.
mily History
ronary artery
ease
Indicate if the patient has/had any direct blood relatives (i.e., parents, s
children) who have had any of the following diagnosed at age 55 y f
relatives or 65 y for female relatives:
● Coronary artery disease (i.e., angina, previous CABG or PCI)
● MI
● Sudden cardiac death without obvious cause
If the patient is adopted or the family history is unavailable, code “No.”
dden cardiac death A first-degree relative (i.e., parent, sibling, child) documented to have d
suddenly of presumed cardiac etiology without other obvious cause
tient Assessment
stolic blood pressure Systolic blood pressure in millimeters mercury
stolic blood
ssure
Diastolic blood pressure in millimeters mercury
ight Measured actual weight in kilograms. To be converted from convention
needed.
ist circumference Average of 2 measurements in centimeters while subject is standing, o
after inspiration and one after expiration. Measurement to be taken at
between the lowest rib and the iliac crest.
ight Measured in centimeters. To be converted from conventional units if ne
art rate Number of heartbeats over 1 min.
he data element/definition is a 2010 PQRI Measures data point (25a).
ACCF indicates American College of Cardiology Foundation; ADA, American
quired immune deficiency syndrome; AR-G, ACTION Registry-Get With the Gu
tery bypass graft; CCS, Canadian Cardiovascular Society; CDC, Centers for D
mography; DNA, deoxyribonucleic acid; DVT, deep venous thrombosis; ECG,
gh-density lipoprotein; HIV, human immunodeficiency virus; KDOQI, Kidney Dis
oprotein; MI, myocardial infarction; MR, magnetic resonance; NKF, National Kid
art Association; PCI, percutaneous coronary intervention; PCR, polymerase cha
-segment elevation myocardial infarction; STS, Society of Thoracic Surgeons;
d VT, ventricular tachycardia.rposely limited (Table 3); the “ACC/AHA/ACR/ASE/ adSNC/HRS/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SIR
08 Key Data Elements and Definitions for Cardiac Imag-
g” document provides a much more extensive list of data
ements, specifically crafted from the perspective of author-
g modality (procedure) reports (18). For example, the
rdiac imaging standards and definitions document notes
at when an exercise stress test is performed, the number
metabolic equivalent tasks achieved, the nature of
duced chest pain, the maximum amount of ST-segment
pression, changes in heart rate and blood pressure, and
her parameters should be recorded as structured data.
owever, from an EHR perspective (the subject of this
cument), the data elements we have specified include the
rdiac diagnostic procedure itself (e.g., stress ECG), date
the procedure, pretest probability, and stress test result
ositive, negative, indeterminate, and adequate or inade-
ate). The clinician is referred to the procedure report for
Value Domain Notes Source
Date
[null]
Minimum data is
year
ACCF/AHA Electrophysiology
Data Standards (16)
in
t
e
Yes
[No]
[null]
ACCF/AHA Acute Coronary
Syndrome Data Standards
(17); AR-G (22); STS Registry
v2.70 (15)
Yes
[No]
[null]
STS Registry v2.70 (15)
Yes
[No]
[null]
ACCF/AHA Cardiac Imaging
Data Standards (18)
Numeric (mm Hg)
Numeric (mm Hg)
Numeric (kg)
int
Numeric (cm) ACCF/AHA Acute Coronary
Syndrome Data Standards (17)
Numeric (cm)
Numeric (bpm)
Association; AF, atrial fibrillation; AHA, American Heart Association; AIDS,
ASA, American Stroke Association; bpm, beats per minute; CABG, coronary
Control and Prevention; CPR, cardiopulmonary resuscitation; CT, computed
rdiogram; EIA, enzyme immunoassay; GFR, glomerular filtration rate; HDL,
utcomes Quality Initiative; LBBB, left bundle-branch block; LDL, low-density
; NSTEMI, non–ST-segment elevation myocardial infarction; NYHA, New York
on; PQRI, Physician Quality Reporting Initiative; RNA, ribonucleic acid; STEMI,
sient ischemic attack; URL, upper reference limit; VF, ventricular fibrillation;has been
f the
ea on ligh
tion, or th
ysical
iac
does not
iblings,
or male
ied
al units if
ne taken
the midpo
eded.
Diabetes
idelines;
isease
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Data Elements and Definitions for EHR July 5, 2011:202–22Similarly, for therapeutic procedures, only key data ele-
ents facilitating clinical care are stressed. For example, for
percutaneous coronary intervention (PCI), in addition to the
tation of PCI, the data to be handled as discrete data would
clude the date of the procedure, lesion treated, and stent-
ecific information. The original procedure report again
ould need to be reviewed should more information be
quired.
Two specific concepts deserve specific mention. Although
e data elements “cardiac diagnostic procedure” and “car-
ac therapeutic procedure” are listed separately in Table 3,
ey can be blended as a single concept at an operational level
.g., left-heart catheterization, PCI). Furthermore, the data
ement set to associate with the concept of a procedure
ould only be that appropriate to the test. The reader is
ferred to the applicable reference document (e.g., for PCI,
e cardiac imaging standards and definitions document [18])
determine which data elements belong together.
The writing committee also notes that the ejection fraction,
ble 2. Laboratory Results Elements
Data Field Definition
Value
Domain Notes Source
boratory Testing
tal cholesterol* 1) Value, 2) units,
and 3) date
Number
Units
Date
iglycerides* 1) Value, 2) units,
and 3) date
Number
Units
Date
L cholesterol* 1) Value, 2) units,
and 3) date
Number
Units
Date
L cholesterol* 1) Value, 2) units,
and 3) date
Number
Units
Date
sting blood sugar 1) Value, 2) units,
and 3) date
Number
Units
Date
eatinine 1) Value, 2) units,
and 3) date
Number
Units
Date
N 1) Value, 2) units,
and 3) date
Number
Units
Date
dium 1) Value, 2) units,
and 3) date
Number
Units
Date
moglobin 1) Value, 2) units,
and 3) date
Number
Units
Date
moglobin A1c 1) Value, 2) units,
and 3) date
Number
Units
Date
matocrit 1) Value, 2) units,
and 3) date
Number
Units
Date
he data element/definition is a 2010 PQRI Measures data point (25a).
BUN indicates blood urea nitrogen; HDL, high-density lipoprotein;
L, low-density lipoprotein; and PQRI, Physician Quality Reporting Initiative.en with a multitude of limitations, is pivotal to patient care, desk modeling, decision support, disease management, and
ality reporting. We wish to reiterate several of the com-
ents and conventions of the cardiac imaging writing group
8) as being highly relevant to the cardiovascular EHR
cabulary. The quantitative determination of systolic func-
on occurs with substantial variability between modalities
d with different reference ranges by modality. Nonetheless,
is quantitative number is purposely included as a single
erived) data element irrespective of modality. Although the
iginal source data and any representation should maintain a
nkage between the calculated ejection fraction and the
iginating modality, the derived ejection fraction is intended
be a single data element regardless of source so that it can
displayed and computed upon in a longitudinal manner,
dependent of modality. In addition, qualitative systolic
nction is to be graded in only 4 categories: normal, mildly
duced, moderately reduced, and severely reduced, with the
nges of quantitative values authored by the cardiac imaging
riting group representing differing degrees of qualitative left
ntricular dysfunction. For example, for purposes of report-
g a quantitative value, the midpoint of the range may be
ed, for example, moderate left ventricular dysfunction is
ported as 35%. Furthermore, quantitative ejection fraction
n be reported as a specific value (e.g., 58%) or a 5% range
.g., 30% to 35%), with the midpoint of a range to be used
r EHR data collection and storage purposes.
.5. Pharmacological Therapy
harmacological therapy data elements (Table 4) are central
many quality reporting initiatives and meaningful use and
e intended to capture whether or not the patient is currently
ceiving or is otherwise prescribed any member of the
edication class in question in the context of the patient
counter. The value domain for pharmacological therapy
ta elements is derived from the National Quality Forum’s
uality Data Set. A response of “yes” is intended to be
tomatically generated if any member of the medication
ass is prescribed. A response of “no” is the default in the
sence of a prescription for the medication class. The
neric value “no” could be replaced by a clinician with “no
clusion” or “no exception” where appropriate (this would
quire active intervention on the part of the clinician).
ypical exclusions include medication allergy or other med-
ation intolerance. Typical exceptions include contraindica-
ons to therapy, such as the patient in heart failure who
herwise qualifies for beta-blocker therapy except for a
sting heart rate of 45 bpm. EHR vendors are strongly
couraged to design systems to autoreport this particular set
variables rather than require clinician input, particularly
hen a medication is prescribed.
.6. Outcomes
he writing committee elected to focus on all-cause mortality
d high-morbidity hospitalization outcomes likely to be
ptured and coded for administrative and billing purposes
able 5). Ongoing efforts through the National Cardiovas-
lar Research Infrastructure project and by the U.S. Food
d Drug Administration as noted below are delineating and
tailing extended concepts of outcomes assessment in both
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Data Field Definition Value Domain Notes Source
agnostic
ocedures
rdiac diagnostic
ocedure
Procedure to evaluate the structure and/or function
of the heart. This lexicon emphasizes common
names for procedure concepts even when various
subprocedures make up the concept (e.g.,
transthoracic echocardiogram, left-heart
catheterization), rather than an unbundled listing of
the subprocedures that make up the procedure
(e.g., CPT code listing). The procedure of greater
complexity should be chosen when the concept of
greater complexity is inclusive of the one of lesser
complexity (e.g., stress echocardiography is
inclusive of TTE). Selected results data (listed in
the next section below) are to be linked to the
study.
● ECG*
● Holter monitor
● Event monitor
● Electrophysiology study
● Transthoracic echocardiography
● Transesophageal echocardiography
● Stress ECG
● Stress echocardiography
● Nuclear stress test
● MRI
● Stress MRI
● Cardiac MR angiography
● Cardiac CT angiography
● CT (noncontrast)
● PET
● Right-heart catheterization
● Biopsy of the right ventricle
● Left-heart catheterization
ECG
Holter monitor
Event monitor
EPS
TTE
TEE
Stress ECG
Stress echo
Nuclear stress test
MRI
Stress MRI
Cardiac MR angiography
Cardiac CT angiography
Computerized tomography
(noncontrast)
CTA
PET
RHC
RVBx
LHC
Values are mutually
exclusive from one
diagnostic area to
the next but not
within one
diagnostic modality.
ACCF/AHA Cardiac Imaging
Data Standards (18)
te of cardiac
agnostic
ocedure
Date of cardiac diagnostic procedure Date Requires month/
year; day if
available
ACCF/AHA Cardiac Imaging
Data Standards (18)
agnostic
ocedure Results
Notes: This is purposely only a partial listing of all
possible results, focusing on the key results with
critical diagnostic, therapeutic, or prognostic
significance. When reported, the result is linked to
the diagnostic test.
ection fraction
uantitative)*
The calculated resting LVEF as either a percentage
value or the midpoint value when a range is
reported
Number ACCF/AHA Cardiac Imaging
Data Standards (18)
ection fraction
ualitative)*
The estimated resting LVEF as a qualitative score:
● Hyperdynamic: 70%
● Normal: 50%–70% (midpoint 60%)
● Mild dysfunction: 40%–49% (midpoint 45%)
● Moderate dysfunction: 30%–39% (midpoint 35%)
● Severe dysfunction: 30% (midpoint 20%)
Hyperdynamic
Normal
Mild dysfunction
Moderate dysfunction
Severe dysfunction
ACCF/AHA Cardiac Imaging
Data Standards (18)
ft ventricle size,
d diastole
uantitative)
Short-axis measurement of the left ventricular
chamber size at end diastole, in centimeters
Number (cm)
ft ventricle size,
d systole
uantitative)
Short-axis measurement of the left ventricular
chamber size at end systole, in centimeters
Number (cm)
ft atrium size
uantitative)
Size of the left atrium, in centimeters Number (cm)
rtic valve area Severity of stenosis of the aortic valve,
in square centimeters
Number (cm2) ACCF/AHA Cardiac Imaging
Data Standards (18)
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Data Field Definition Value Domain Notes Source
rtic valve
gurgitation
Severity of regurgitation through the aortic valve:
● None
● Mild
● Moderate
● Severe
None
Mild
Moderate
Severe
ACCF/AHA Cardiac Imaging
Data Standards (18)
itral valve area Severity of stenosis of the mitral valve,
in square centimeters
Number (cm2) ACCF/AHA Cardiac Imaging
Data Standards (18)
itral valve
gurgitation
Severity of regurgitation through the mitral valve:
● None
● Mild
● Moderate
● Severe
None
Mild
Moderate
Severe
ACCF/AHA Cardiac Imaging
Data Standards (18)
ress test result Result of functional cardiac testing evaluating for
evidence of myocardial ischemia
Normal
Abnormal
Indeterminate
ACCF/AHA Cardiac Imaging
Data Standards (18)
yocardium
hemic amount
ualitative)
Qualitative amount of myocardium estimated to be
ischemic per functional study (e.g.,
echocardiogram, MRI, SPECT)
None
Small
Medium
Large
ronary calcium
ore
Agatston score of estimate of extent of coronary
calcification by coronary CT
Number ACCF/AHA Cardiac Imaging
Data Standards (18)
ronary artery
mber of
seased vessels
xcludes left
ain disease)
Number of major epicardial vessels and major
branches of epicardial vessels with 70% luminal
obstruction:
● None
● 1
● 2
● 3
0
1
2
3
ft main
ronary artery
enosis
Left main coronary disease is present when there
is 50% compromise of vessel diameter.
Yes
No
[null]
STS Registry v2.70 (15)
oximal LAD
ronary artery
enosis
Luminal narrowing of the proximal LAD at the
point of maximal stenosis is 70%.
Yes
No
[null]
ird-degree AV
ock (complete
art block)
Heart rhythm characterized by independent atrial
and ventricular complexes with atrial rate usually
exceeding ventricular rate
Yes
No
[null]
ACCF/AHA
Electrophysiology Data
Standards (16)
ft bundle-
anch block
ECG pattern of LBBB characterized by QRS
duration of 120 ms, delayed onset of intrinsicoid
deflection in leads 1, V5, and V6 60 ms; broad
and notched or slurred R waves in I, aVL, V5, and
V6; RS or QS complexes in right precordial leads;
ST segment and T waves in opposite polarity to
the major QRS deflection
Yes
No
[null]
ACCF/AHA
Electrophysiology Data
Standards (16)
traventricular
nduction delay
onspecific)
ECG pattern of intraventricular conduction delay
characterized by QRS duration 110 ms that does
not meet morphology criteria of LBBB or RBBB
Yes
No
[null]
ACCF/AHA
Electrophysiology Data
Standards (16)
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Data Field Definition Value Domain Notes Source
erapeutic
ocedures
rdiac
erapeutic
ocedure
Procedure to treat pathologic
structural/pathophysiological functional disorder of
the heart. This lexicon emphasizes common names
for procedure concepts even when various
subprocedures make up the concept (e.g., CRT,
PCI) rather than an unbundled listing of the
subprocedures that make up the procedure (e.g.,
CPT code listing). The procedure of greatest
complexity should be chosen when the concept of
greater complexity is inclusive of the one of lesser
complexity (e.g., ICD is inclusive of pacemaker).
Selected results data (listed in the next section
below) are to be linked to the study:
● Ablation, atrial (e.g., for AF)
● Ablation, ventricular (e.g., for VT)
● Ablation, other (e.g., reciprocating tachycardia
ablation)
● Pacemaker
● ICD
● CRT
● Lead extraction
● Electrical cardioversion
● Chemical cardioversion
● PCI
● Septal ablation
● Transcatheter aortic valve implant
● Closure device, atrial
● Closure device, ventricular
● CABG
● Aortic balloon valvotomy
● Aortic valve replacement
● Mitral valve repair
● Mitral valve replacement
● Mitral balloon valvotomy
● Mitral commissurotomy
● Percutaneous mitral repair
● Tricuspid valve repair
● Tricuspid valve replacement
● Pulmonic valvuloplasty
● Pulmonary valve replacement
● Surgical maze
● Pericardiocentesis
● Pericardial window
● Pericardial stripping
● Left atrial appendage occlusion
● Ventricular aneurysm resection
● Left VAD
● Right VAD
● Heart transplant
Ablation, atrial
Ablation, ventricular
Ablation, other
Pacemaker
ICD
CRT
Lead extraction
Electrical cardioversion
Chemical cardioversion
PCI
Septal ablation
Transcatheter aortic valve
implant
Closure device, atrial
Closure device, ventricular
CABG
Aortic balloon valvotomy
Aortic valve replacement
Mitral valve repair
Mitral valve replacement
Mitral balloon valvotomy
Mitral commissurotomy
Percutaneous mitral repair
Tricuspid valve repair
Tricuspid valvuloplasty
Pulmonary valvuloplasty
Pulmonary valve replacement
Surgical maze
Pericardiocentesis
Pericardial window
Pericardial stripping
Left atrial appendage occlusion
Aneurysmectomy
VAD, left
VAD, right
Heart transplant
Values are mutually
exclusive from one
therapeutic area to
the next but not
within one
therapeutic
modality.
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Data Elements and Definitions for EHR July 5, 2011:202–22e inpatient and outpatient arenas and should become avail-
le in 2011.
. Formalization of Terms and
xtension of Vocabulary
he foundational work to create a base cardiovascular data
ement set for EHRs is a component of a broader program to
dress the cardiovascular data standard needs of the clinical
mmunity, secondary stakeholders, ACCF, and AHA. The
erarching program is being coordinated under 2 organizations
artered to lead the development of clinical data standards for
ble 3. Continued
Data Field Definition
te of
erapeutic
ocedure
Date of cardiac therapeutic procedure Da
if
erapeutic
ocedure Device
plants
planted device Type of device implanted
● Single-chamber pacemaker
● Dual-chamber pacemaker
● Biventricular pacemaker
● Cardioverter-defibrillator
● Cardioverter-defibrillator with resynchronization
● Atrial lead, right
● Atrial lead, left
● Ventricular lead, right
● Ventricular lead, left
● Bare-metal stent
● Drug-eluting stent
● Closure device, atrial
● Closure device, ventricular
● Aortic valve, mechanical
● Aortic valve, tissue
● Aortic valve, transcutaneous
● Mitral valve, mechanical
● Mitral valve, tissue
● Left VAD
● Right VAD
● Total artificial heart
Sin
Du
Biv
Ca
Ca
Atr
Atr
Ve
Ve
Ba
Dr
Clo
Clo
Ao
Ao
Ao
Mi
Mi
VA
VA
To
anufacturer Manufacturer of the implanted device Te
odel Model of the implanted device Te
rial number Serial number of the implanted device, if
applicable
Te
vice
rameters
Key manufacturer’s specification of the implanted
device (e.g., size of stent)
Te
ronary lesions
ated
Per the CASS coronary artery segment map,
lesion(s) treated during a PCI procedure.
Te
ronary graft
astomoses
Per the CASS coronary artery segment map,
anastomoses placed during a CABG procedure.
Te
he data element/definition is a 2010 PQRI Measures data point (25a).
ACCF indicates American College of Cardiology; AF, atrial fibrillation; AHA, A
pass graft; CASS, Coronary Artery Surgery Study; CPT, Code of Procedural Ter
mputed tomography angiography; ECG, electrocardiogram; EPS, electrophysiolo
BB, left bundle-branch block; LHC, left-heart catheterization; LVEF, left ventri
I, percutaneous coronary intervention; PET, positron emission tomography; P
ht-heart catheterization; RVBx, right ventricular endomyocardial biopsy; SPECT
E, transesophageal echocardiogram; TTE, transthoracic echocardiogram; VADalth care and research: Health Level Seven International coL7) and the Clinical Data Interchange Standards Consortium.
his project will organize multiple complementary initiatives to
nerate a single set of materials authoritatively defining the data
quirements of the cardiovascular domain. Specifically, the
itiatives include the ACCF/AHA cardiovascular data elements
scribed herein, the U.S. Food and Drug Administration effort
define cardiovascular endpoint definitions and associated data
ed in regulated clinical trials, and the joint ACC/Duke Clinical
esearch Institute collaboration to build a national cardiovascu-
r research infrastructure. These initiatives, working in concert,
ill collectively result in a common set of data elements, with
sociated controlled terminology, relationships, and workflow
alue Domain Notes Source
ires month/year; day
)
mber pacemaker
ber pacemaker
ar pacemaker
r-defibrillator
r-defibrillator–
hronization
, right
, left
lead, right
lead, left
l stent
g stent
vice, atrial
vice, ventricular
e, mechanical
e, tissue
e, transcutaneous
e, mechanical
e, tissue
cial heart
Each implanted
device is to be
associated with a
manufacturer,
model, serial
number, and device
parameters as
appropriate for the
device.
Heart Association; AV block, atrioventricular block; CABG, coronary artery
es; CRT, cardiac resynchronization therapy; CT, computed tomography; CTA,
udy; ICD, implantable cardioverter-defibrillator; LAD, left anterior descending;
ction fraction; MR, magnetic resonance; MRI, magnetic resonance imaging;
ysician Quality Reporting Initiative; RBBB, right bundle-branch block; RHC,
photon emission computed tomography; STS, Society of Thoracic Surgeons;
ular assist device; and VT, ventricular tachycardia.V
te (requ
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Data Field Definition Value Domain Notes Source
armacological Therapy Note: The data elements in this section are derived from the patient medication list
(rather than explicitly entered by the provider) to capture whether or not the patient
is currently receiving the pharmacological therapy or if the pharmacological therapy
was prescribed during the present encounter.
pirin* Yes
No
No—exclusion
No—exception
Y12 blocker Yes
No
No—exclusion
No—exception
nsteroidal anti-inflammatory This does not include aspirin or cyclo-oxygenase 2 inhibitors. Yes
No
No—exclusion
No—exception
eroid, systemic This does not include topical or inhaled steroid therapy. Yes
No
No—exclusion
No—exception
clo-oxygenase 2 inhibitor Yes
No
No—exclusion
No—exception
ticoagulant* Yes
No
No—exclusion
No—exception
ta blocker* Yes
No
No—exclusion
No—exception
pha blocker Yes
No
No—exclusion
No—exception
E inhibitor* Yes
No
No—exclusion
No—exception
B Yes
No
No—exclusion
No—exception
lcium channel blocker Yes
No
No—exclusion
No—exception
tiarrhythmics Yes
No
No—exclusion
No—exception
rect rennin inhibitors Yes
No
No—exclusion
No—exception
trate Yes
No
No—exclusion
No—exception
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tandards Harmonization, and HL7 Clinical Interoperability
ouncil standards development processes and managed in a
andards-based, publicly accessible data element repository.
The ultimate destination, the interchange of clinical data
quired as an integrated process in the delivery of care, has
ultiple potential benefits: reuse of data for decision support and
sease management, dissemination of consistent and well-
rmed data to stakeholders, and efficiencies in integration of
inical processes into the clinical research context. Underpin-
ng these goals is the requirement of semantic interoperability,
goal we believe will be furthered by the adoption of common
rdiovascular data elements for EHRs.
ble 4. Continued
Data Field Definit
atin*
nstatin antilipidemic*
sulin
ninsulin hypoglycemic
uretic
dosterone receptor antagonist
he data element/definition is a 2010 PQRI Measures data point (25a).
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blo
ble 5. Outcomes Data Elements
ata Field Definition
Value
Domain Notes Source
tcomes
ath Death includes
all deaths
regardless of
etiology.
Yes
No
ACCF/AHA Atrial
Fibrillation Data
Standards (19)
te of
ath
Date
ACCF indicates American College of Cardiology Foundation; and AHA,
erican Heart Association.taff
merican College of Cardiology Foundation
hn C. Lewin, MD, Chief Executive Officer
harlene May, Senior Director, Science and Clinical Policy
elanie Shahriary, RN, BSN, Director, Performance Measures
and Data Standards
aniel Roman, Senior Specialist, ACC Health Information
Technology
merican College of Cardiology Foundation/
merican Heart Association
aria Lizza D. Isler, BSMT, Specialist, Clinical Data
Standards
merican Heart Association
ancy Brown, Chief Executive Officer
ose Marie Robertson, MD, FACC, FAHA, Chief Science
Officer
ayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice
President, Office of Science Operations
ark D. Stewart, MPH, Science and Medicine Advisor,
Office of Science Operations
dy Hundley, Production Manager, Scientific Publishing,
Office of Science Operations
Value Domain Notes Source
Yes
No
No—exclusion
No—exception
Yes
No
No—exclusion
No—exception
Yes
No
No—exclusion
No—exception
Yes
No
No—exclusion
No—exception
Yes
No
No—exclusion
No—exception
Yes
No
No—exclusion
No—exception
d PQRI, Physician Quality Reporting Initiative.ion
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